1. Exploring the Spectrum of Excessive Daytime Sleepiness

3. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States.

4. Background

5. Impact of Sleep Restriction

6. Defining EDS

7. Differentiating EDS and Fatigue

8. Prevalence of EDS

9. Prevalence of EDS (cont)

10. Impact of EDS

11. Case 1

12. Causes of EDS

13. Case 1: Differential Diagnosis

14. Screening Tools for Sleep Disorders

15. Case 1: Sleep History

16. Case 1: Evaluation

17. Case 1: Testing Results

18. Behavioral Management of EDS in Narcolepsy

19. FDA-Approved Therapies: Narcolepsy

20. Emerging Therapies: Narcolepsy

21. Factors in Initial Treatment Selection for Narcolepsy

22. Combination Trial: Design

23. Combination Trial: Results

24. Case 2

25. Case 2: History

26. Case 2: Findings

27. Case 2: Differential Diagnosis

28. Case 2: Plan

29. Case 2: Split-Night Study

30. Case 2: Return Visit 4 Weeks After Obtaining CPAP

31. Case 2: PAP-Nap

32. Case 2: Visit 6 Weeks Later Findings and Diagnosis

33. EDS Remains After Optimal Treatment of OSA With CPAP

34. Residual Sleepiness in OSA

35. Treatment of Residual Sleepiness in OSA

36. Conclusions

37. Abbreviations

38. Abbreviations (cont)